首页 › 基金 › Lion Point Capital, LP › SRPT
Lion Point Capital, LP 对 SRPT 的持仓历史
SAREPTA THERAPEUTICS INC · 医疗保健
Lion Point Capital, LP 在 Q3 2026 的 13F 申报中披露持有 SRPT(SAREPTA THERAPEUTICS INC)28,500 股,市值约 US$519K,约占其申报组合的 3.01%,在其申报持仓中市值排名第 13 位。 Lion Point Capital, LP 最近 4 个申报季度中有 4 个季度披露了 SRPT 持仓,最早可追溯至 Q4 2025。
最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR
Lion Point Capital, LP 对 SRPT 的持仓演变
Lion Point Capital, LP 于 Q4 2025 首次披露 SRPT 持仓:28,500 股(约 US$613K)。 该持仓在 Q1 2026 达到峰值 28,500 股,市值约 US$620K。 在 4 次申报中,Lion Point Capital, LP 的持股数量始终未变。 最近一期申报(Q3 2026)显示持股 28,500 股、市值约 US$519K。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2025 | 28.50K | $613.32K | 新进 |
| Q1 2026 | 28.50K | $620.16K | 持有 |
| Q2 2026 | 28.50K | $512.14K | 持有 |
| Q3 2026 | 28.50K | $519.27K | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 SRPT 与 13F 数据
SRPT(SAREPTA THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 12 只申报持有 SRPT,申报仓位最大的包括:HIGHBRIDGE CAPITAL MANAGEMENT LLC (US$50.3M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
更多关于 Lion Point Capital, LP
常见问题
How long has Lion Point Capital, LP held SRPT?
Lion Point Capital, LP has disclosed SRPT holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Lion Point Capital, LP's current position in SRPT?
As of Q3 2026, Lion Point Capital, LP holds 28.50K shares of SRPT (SAREPTA THERAPEUTICS INC), valued at $519.27K, representing 3.01% of its reported portfolio and ranking #13.
Has Lion Point Capital, LP been buying or selling SRPT?
In the latest 13F filing (Q3 2026), Lion Point Capital, LP held unchanged its position in SRPT. The position peaked in Q1 2026 at 28.50K shares.
Which other funds hold SRPT?
Other major institutional holders of SRPT include HIGHBRIDGE CAPITAL MANAGEMENT LLC, among 12 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.